Document_and_Entity_Informatio
Document and Entity Information | 3 Months Ended | |
Mar. 31, 2014 | 9-May-14 | |
Document And Entity Information [Abstract] | ' | ' |
Document Type | '10-Q | ' |
Amendment Flag | 'false | ' |
Document Period End Date | 31-Mar-14 | ' |
Document Fiscal Year Focus | '2014 | ' |
Document Fiscal Period Focus | 'Q1 | ' |
Trading Symbol | 'NANX | ' |
Entity Registrant Name | 'NANOPHASE TECHNOLOGIES CORPORATION | ' |
Entity Central Index Key | '0000883107 | ' |
Current Fiscal Year End Date | '--12-31 | ' |
Entity Filer Category | 'Smaller Reporting Company | ' |
Entity Common Stock, Shares Outstanding | ' | 28,481,496 |
BALANCE_SHEETS
BALANCE SHEETS (USD $) | Mar. 31, 2014 | Dec. 31, 2013 |
In Thousands, unless otherwise specified | ||
Current assets: | ' | ' |
Cash and cash equivalents | $2,148 | $3,276 |
Investments | 30 | 30 |
Trade accounts receivable, less allowance for doubtful accounts of $6 on March 31, 2014 and December 31, 2013 | 1,130 | 52 |
Other receivables | ' | 1 |
Inventories, net | 931 | 976 |
Prepaid expenses and other current assets | 250 | 202 |
Total current assets | 4,489 | 4,537 |
Equipment and leasehold improvements, net | 2,319 | 2,464 |
Other assets, net | 27 | 27 |
Total assets | 6,835 | 7,028 |
Current liabilities: | ' | ' |
Current portion of capital lease obligations | 31 | 31 |
Accounts payable | 754 | 503 |
Accrued expenses | 259 | 323 |
Total current liabilities | 1,044 | 857 |
Long-term portion of capital lease obligations | 3 | 10 |
Long-term deferred rent | 630 | 633 |
Asset retirement obligations | 161 | 160 |
Total long-term liabilities | 794 | 803 |
Stockholders' equity: | ' | ' |
Preferred stock, $.01 par value, 24,088 shares authorized and no shares issued and outstanding | ' | ' |
Common stock, $.01 par value, 35,000,000 shares authorized; 28,481,496 shares issued and outstanding on March 31, 2014 and December 31, 2013 | 285 | 285 |
Additional paid-in capital | 95,819 | 95,761 |
Accumulated deficit | -91,107 | -90,678 |
Total stockholders' equity | 4,997 | 5,368 |
Total liabilities and stockholders' equity | $6,835 | $7,028 |
BALANCE_SHEETS_Parenthetical
BALANCE SHEETS (Parenthetical) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 |
In Thousands, except Share data, unless otherwise specified | ||
Statement Of Financial Position [Abstract] | ' | ' |
Trade accounts receivable, less allowance for doubtful accounts | $6 | $6 |
Preferred stock, par value | $0.01 | $0.01 |
Preferred stock, shares authorized | 24,088 | 24,088 |
Preferred stock, shares issued | ' | ' |
Preferred stock, shares outstanding | ' | ' |
Common stock, par value | $0.01 | $0.01 |
Common stock, shares authorized | 35,000,000 | 35,000,000 |
Common stock, shares issued | 28,481,496 | 28,481,496 |
Common stock, shares outstanding | 28,481,496 | 28,481,496 |
STATEMENTS_OF_OPERATIONS_Unaud
STATEMENTS OF OPERATIONS (Unaudited) (USD $) | 3 Months Ended | |
In Thousands, except Share data, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Revenue: | ' | ' |
Product revenue | $2,576 | $2,976 |
Other revenue | 9 | 3 |
Total revenue | 2,585 | 2,979 |
Operating expense: | ' | ' |
Cost of revenue | 1,877 | 2,073 |
Gross profit | 708 | 906 |
Research and development expenses | 337 | 429 |
Selling, general and administrative expenses | 798 | 960 |
Loss from operations | -427 | -483 |
Interest expense | -2 | -7 |
Other, net | ' | 6 |
Loss before provision for income taxes | -429 | -484 |
Provision for income taxes | ' | ' |
Net loss | ($429) | ($484) |
Net loss per share-basic and diluted | ($0.02) | ($0.02) |
Weighted average number of basic and diluted common shares outstanding | 28,481,496 | 28,466,717 |
STATEMENTS_OF_CASH_FLOWS_Unaud
STATEMENTS OF CASH FLOWS (Unaudited) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Operating activities: | ' | ' |
Net loss | ($429) | ($484) |
Adjustments to reconcile net loss to net cash used in operating activities: | ' | ' |
Depreciation and amortization | 187 | 226 |
Gain on disposal of equipment | ' | -6 |
Stock compensation expense | 57 | 77 |
Changes in assets and liabilities related to operations: | ' | ' |
Trade accounts receivable | -1,078 | -202 |
Other accounts receivable | 1 | 25 |
Inventories | 45 | 117 |
Prepaid expenses and other assets | -48 | -119 |
Accounts payable | 264 | 54 |
Accrued expenses | -67 | -117 |
Net cash used in operating activities | -1,068 | -429 |
Investing activities: | ' | ' |
Proceeds from disposal of equipment | ' | 6 |
Acquisition of equipment and leasehold improvements | -30 | -42 |
Payment of accounts payable incurred for the purchase of equipment and leasehold improvements | -23 | -20 |
Net cash used in investing activities | -53 | -56 |
Financing activities: | ' | ' |
Principal payments on capital leases | -7 | -34 |
Proceeds from exercise of stock options | ' | 3 |
Net cash used in financing activities | -7 | -31 |
Decrease in cash and cash equivalents | -1,128 | -516 |
Cash and cash equivalents at beginning of period | 3,276 | 4,124 |
Cash and cash equivalents at end of period | 2,148 | 3,608 |
Supplemental cash flow information: | ' | ' |
Interest paid | 1 | 7 |
Supplemental non-cash investing and financing activities: | ' | ' |
Accounts payable incurred for the purchase of equipment and leasehold improvements | $10 | $7 |
Basis_of_Presentation
Basis of Presentation | 3 Months Ended |
Mar. 31, 2014 | |
Accounting Policies [Abstract] | ' |
Basis of Presentation | ' |
(1) Basis of Presentation | |
The accompanying unaudited interim financial statements of Nanophase Technologies Corporation (“Nanophase” or the “Company”, including “we”, “our” or “us”) reflect all adjustments (consisting of normal recurring adjustments) which, in the opinion of management, are necessary for a fair presentation of our financial position and operating results for the interim periods presented. Operating results for the three months ended March 31, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. | |
These financial statements should be read in conjunction with our audited financial statements and notes thereto for the year ended December 31, 2013, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the Securities and Exchange Commission. |
Description_of_Business
Description of Business | 3 Months Ended |
Mar. 31, 2014 | |
Accounting Policies [Abstract] | ' |
Description of Business | ' |
(2) Description of Business | |
Nanophase is a nanomaterials and applications developer and commercial manufacturer with an integrated family of nanomaterial technologies. We produce engineered nano and sub-micron materials for use in a variety of diverse existing and developing markets: personal care including sunscreens, architectural coatings, industrial coating applications, abrasion-resistant additives, plastics additives, medical diagnostics, energy and a variety of surface finishing technologies (polishing) applications. We target markets in which we believe practical solutions may be found using our products. We work closely with current and potential customers in these target markets to identify their material and performance requirements and market our materials to various end-use applications manufacturers. Recently developed technologies have made certain new products possible and opened potential new markets. Although our primary strategic focus has been the North American market, we currently sell our material to customers overseas and have been working to expand our reach within foreign markets. | |
The Company was incorporated in Illinois on November 25, 1989, and became a Delaware corporation in November 1997. Our common stock trades on the OTCQB marketplace under the symbol NANX. | |
While product sales comprise the overwhelming majority of our revenue, we also recognize revenue from other sources from time to time. These activities are not expected to drive the long-term growth of the business. For this reason we classify such revenue as “other revenue” in our Statement of Operations, as it does not represent revenue directly from our nanocrystalline materials. | |
The presentation of certain prior year disclosures has been modified to conform to current year presentation, as financial data is now presented in thousands of dollars rather than in dollars. |
Financial_Instruments
Financial Instruments | 3 Months Ended |
Mar. 31, 2014 | |
Fair Value Disclosures [Abstract] | ' |
Financial Instruments | ' |
(3) Financial Instruments | |
We follow the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. | |
Our financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued expenses. The fair values of all financial instruments were not materially different from their carrying values. |
Investments
Investments | 3 Months Ended |
Mar. 31, 2014 | |
Investments Debt And Equity Securities [Abstract] | ' |
Investments | ' |
(4) Investments | |
Investments on March 31, 2014 and December 31, 2013 were comprised of certificates of deposit in the amount of $30, pledged as collateral for our rent and restricted as to withdrawal or usage. |
Inventories
Inventories | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Inventory Disclosure [Abstract] | ' | ||||||||
Inventories | ' | ||||||||
(5) Inventories | |||||||||
Inventories consist of the following: | |||||||||
March 31, | December 31, | ||||||||
2014 | 2013 | ||||||||
Raw materials | $ | 160 | $ | 132 | |||||
Finished goods | 823 | 896 | |||||||
983 | 1,028 | ||||||||
Allowance for excess inventory quantities | (52 | ) | (52 | ) | |||||
$ | 931 | $ | 976 |
ShareBased_Compensation
Share-Based Compensation | 3 Months Ended | ||||
Mar. 31, 2014 | |||||
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | ' | ||||
Share-Based Compensation | ' | ||||
(6) Share-Based Compensation | |||||
We follow FASB ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. We recognized compensation expense related to stock options of $57 and $69 for the three month periods ended March 31, 2014 and 2013, respectively. | |||||
As of March 31, 2014, there was approximately $410 of total unrecognized compensation cost related to nonvested share-based compensation arrangements granted under our stock option plans. That cost is expected to be recognized over a remaining weighted-average period of 2.3 years. | |||||
Stock Options and Stock Grants | |||||
During the three months ended March 31, 2014, no stock options were exercised, compared to proceeds of $3 realized and 10,000 shares of common stock issued pursuant to option exercises during the same period in 2013. For the three months ended March 31, 2014, 568,000 stock options were granted compared to 543,000 stock options granted during the same period in 2013. During the three months ended March 31, 2014, no stock options were forfeited compared to 54,000 stock options forfeited during the same period in 2013. | |||||
Stock Appreciation Rights | |||||
Prior to 2011, we granted our outside directors stock appreciation rights (SARs). The change in fair value of the awards granted during prior years is included in non-cash compensation expense for the quarters ended March 31, 2014 and 2013. The SARs granted vested immediately and are payable upon the directors’ removal or resignation from the position of director. These awards are accounted for as liability awards, included in accrued expenses as of March 31, 2014 and 2013, and adjusted to fair value each reporting period. The fair value of the liability on March 31, 2014 was $7, compared to $8 on December 31, 2013. | |||||
As of March 31, 2014, we did not have any unvested restricted stock or performance shares outstanding. | |||||
The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for stock options granted during the three month periods ended: | |||||
March 31, | March 31, | ||||
2014 | 2013 | ||||
Weighted-average risk-free interest rates: | 2.01% | 1.32% | |||
Dividend yield: | — | — | |||
Weighted-average expected life of the option: | 7 years | 7 years | |||
Weighted-average expected stock price volatility: | 95.16% | 92.27% | |||
Weighted-average fair value of the options granted: | $0.42 | $0.33 |
Significant_Customers_and_Cont
Significant Customers and Contingencies | 3 Months Ended |
Mar. 31, 2014 | |
Text Block [Abstract] | ' |
Significant Customers and Contingencies | ' |
(7) Significant Customers and Contingencies | |
Sales to three customers constituted approximately 80%, 6% and 2%, respectively, of our total revenue for the three months ended March 31, 2014. Amounts included in accounts receivable on March 31, 2014 relating to these three customers were approximately $784, $144 and $57, respectively. Revenue from these three customers constituted approximately 79%, 7% and 5%, respectively, of our total revenue for the three months ended March 31, 2013. Amounts included in accounts receivable on March 31, 2013 relating to these three customers were approximately $857, $201 and $78, respectively. The loss of one of these significant customers or the failure to attract new customers could have a material adverse effect on our business, results of operations and financial condition. | |
We currently have exclusive supply agreements with BASF Corporation (“BASF”), our largest customer, that have contingencies outlined which could potentially result in the license of technology and/or the sale of production equipment from the Company to the customer intended to provide capacity sufficient to meet the customer’s production needs. This outcome may occur if we fail to meet certain performance requirements, certain other obligations and/or certain financial condition covenants. The financial condition covenants in one of our supply agreements with BASF “trigger” a technology transfer right (license and equipment sale at BASF’s option) in the event (a) that earnings for the twelve month period ending with our most recently published quarterly financial statements are less than zero and our cash, cash equivalents and certain investments are less than $1 million, or (b) of an acceleration of any debt maturity having a principal amount of more than $10 million. Our supply agreements with BASF also “trigger” a technology transfer right in the event of our insolvency, as further defined within the agreements. In the event of an equipment sale, upon incurring a triggering event, the equipment would be sold to the customer at either 115% of the equipment’s net book value or the greater of 30% of the original book value of such equipment, and any associated upgrades to it, or 115% of the equipment’s net book value, depending on the contract and related equipment. | |
We believe that we have sufficient cash, (See Liquidity and Capital Resources in Management’s Discussion and Analysis in Part I, Item 2 of this Form 10-Q for a further discussion) to operate our business during 2014. If a triggering event were to occur and BASF elected to proceed with the license and related equipment sale mentioned above, we would receive royalty payments from this customer for products sold using our technology; however, we would lose both significant revenue and the ability to generate significant revenue to replace that which was lost in the near term. Replacement of necessary equipment that could be purchased and removed by the customer pursuant to this triggering event could take in excess of twelve months. Any additional capital outlays required to rebuild capacity would probably be greater than the proceeds from the purchase of the assets as dictated by our agreement with the customer. Similar consequences would occur if we were determined to have materially breached certain other provisions of the supply agreement with BASF. Any such event would also likely result in the loss of many of our key staff and line employees due to economic realities. We believe that our employees are a critical component of our success and it could be difficult to replace them quickly. Given the occurrence of any such event, we might not be able to hire and retain skilled employees given the stigma relating to such an event and its impact on us. Finally, any shortfall in capital needed to operate the business as management intends, including with respect to avoiding this triggering event as described above, may result in a curtailment of certain activities or anticipated investments. |
Business_Segmentation_and_Geog
Business Segmentation and Geographical Distribution | 3 Months Ended |
Mar. 31, 2014 | |
Segment Reporting [Abstract] | ' |
Business Segmentation and Geographical Distribution | ' |
(8) Business Segmentation and Geographical Distribution | |
Revenue from international sources approximated $111 and $78 for the three months ended March 31, 2014 and 2013, respectively. All of this revenue was product revenue. | |
Our operations comprise a single business segment and all of our long-lived assets are located within the United States. |
Financial_Instruments_Policies
Financial Instruments (Policies) | 3 Months Ended |
Mar. 31, 2014 | |
Fair Value Disclosures [Abstract] | ' |
Fair Value Measurements and Disclosures | ' |
We follow the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. | |
Share-Based Payments | ' |
We follow FASB ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. We recognized compensation expense related to stock options of $57 and $69 for the three month periods ended March 31, 2014 and 2013, respectively. |
Inventories_Tables
Inventories (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Inventory Disclosure [Abstract] | ' | ||||||||
Summary of Inventories | ' | ||||||||
Inventories consist of the following: | |||||||||
March 31, | December 31, | ||||||||
2014 | 2013 | ||||||||
Raw materials | $ | 160 | $ | 132 | |||||
Finished goods | 823 | 896 | |||||||
983 | 1,028 | ||||||||
Allowance for excess inventory quantities | (52 | ) | (52 | ) | |||||
$ | 931 | $ | 976 | ||||||
ShareBased_Compensation_Tables
Share-Based Compensation (Tables) | 3 Months Ended | ||||
Mar. 31, 2014 | |||||
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | ' | ||||
Schedule of Assumptions Used to Calculate Black-Scholes Option Pricing Model for Stock Options Granted | ' | ||||
The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for stock options granted during the three month periods ended: | |||||
March 31, | March 31, | ||||
2014 | 2013 | ||||
Weighted-average risk-free interest rates: | 2.01% | 1.32% | |||
Dividend yield: | — | — | |||
Weighted-average expected life of the option: | 7 years | 7 years | |||
Weighted-average expected stock price volatility: | 95.16% | 92.27% | |||
Weighted-average fair value of the options granted: | $0.42 | $0.33 |
Investments_Additional_Informa
Investments - Additional Information (Detail) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 |
In Thousands, unless otherwise specified | ||
Investments All Other Investments [Abstract] | ' | ' |
Certificates of deposit | $30 | $30 |
Inventories_Summary_of_Invento
Inventories - Summary of Inventories (Detail) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 |
In Thousands, unless otherwise specified | ||
Inventory Disclosure [Abstract] | ' | ' |
Raw materials | $160 | $132 |
Finished goods | 823 | 896 |
Inventory gross, Total | 983 | 1,028 |
Allowance for excess inventory quantities | -52 | -52 |
Inventories net, Total | $931 | $976 |
ShareBased_Compensation_Additi
Share-Based Compensation - Additional Information (Detail) (USD $) | 3 Months Ended | ||
In Thousands, except Share data, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2013 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
Share-based compensation expense | $57 | $69 | ' |
Total unrecognized compensation cost related to nonvested share-based compensation arrangements granted | 410 | ' | ' |
Weighted-average period over which unrecognized compensation is expected to be recognized | '2 years 3 months 18 days | ' | ' |
Proceeds from exercise of stock options | ' | 3 | ' |
Common stock issued pursuant to option exercises | 0 | 10,000 | ' |
Stock options granted | 568,000 | 543,000 | ' |
Stock options forfeited | 0 | 54,000 | ' |
Common stock, shares outstanding | 28,481,496 | ' | 28,481,496 |
Stock Appreciation Rights (SARs) [Member] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
Fair value of the liability | $7 | ' | 8 |
Restricted Stock [Member] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
Common stock, shares outstanding | 0 | ' | ' |
Performance Shares [Member] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
Common stock, shares outstanding | 0 | ' | ' |
ShareBased_Compensation_Schedu
Share-Based Compensation - Schedule of Assumptions Used to Calculate Black-Scholes Option Pricing Model for Stock Options Granted (Detail) (USD $) | 3 Months Ended | |
Mar. 31, 2014 | Mar. 31, 2013 | |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract] | ' | ' |
Weighted-average risk-free interest rates | 2.01% | 1.32% |
Dividend yield | ' | ' |
Weighted-average expected life of the option | '7 years | '7 years |
Weighted-average expected stock price volatility | 95.16% | 92.27% |
Weighted-average fair value of the options granted | $0.42 | $0.33 |
Significant_Customers_and_Cont1
Significant Customers and Contingencies - Additional Information (Detail) (USD $) | 3 Months Ended | 3 Months Ended | 3 Months Ended | 3 Months Ended | 3 Months Ended | ||||||||||||
Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | |
Customer | Customers One [Member] | Customers One [Member] | Customers One [Member] | Customers One [Member] | Customers Two [Member] | Customers Two [Member] | Customers Two [Member] | Customers Two [Member] | Customers Three [Member] | Customers Three [Member] | Customers Three [Member] | Customers Three [Member] | BASF [Member] | BASF [Member] | BASF [Member] | ||
Sales [Member] | Sales [Member] | Sales [Member] | Sales [Member] | Sales [Member] | Sales [Member] | Maximum [Member] | Minimum [Member] | ||||||||||
Revenue, Major Customer [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of major customers | 3 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenue from top customers | ' | ' | ' | ' | 80.00% | 79.00% | ' | ' | 6.00% | 7.00% | ' | ' | 2.00% | 5.00% | ' | ' | ' |
Accounts receivable | $1,130,000 | $52,000 | $784,000 | $857,000 | ' | ' | $144,000 | $201,000 | ' | ' | $57,000 | $78,000 | ' | ' | ' | ' | ' |
Supply agreements with BASF Corporation | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 'The financial condition covenants in one of our supply agreements with BASF btriggerb a technology transfer right (license and equipment sale at BASFbs option) in the event (a) that earnings for the twelve month period ending with our most recently published quarterly financial statements are less than zero and our cash, cash equivalents and certain investments are less than $1 million, or (b) of an acceleration of any debt maturity having a principal amount of more than $10 million. | ' | ' |
Cash, cash equivalents and investments, maximum | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,000,000 | ' |
Minimum contractual covenant - net earnings previous twelve months | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' |
Principal amount of debt on maturity, minimum | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $10,000,000 |
Net book value equipment | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 115.00% | ' | ' |
Original book value of equipment, Minimum | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 30.00% |
Business_Segmentation_and_Geog1
Business Segmentation and Geographical Distribution - Additional Information (Detail) (Non-Domestic Revenue [Member], USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Non-Domestic Revenue [Member] | ' | ' |
Revenue from External Customer [Line Items] | ' | ' |
Revenue from international sources | $111 | $78 |